Vera Therapeutics (VERA) said Monday it has secured an exclusive license deal with Stanford University for fusion protein targeting BAFF and APRIL, known as VT-109, with therapeutic potential across the spectrum of B cell mediated diseases.
Vera said it will develop and market VT-109 in exchange for undisclosed upfront and milestone payments as part of the agreement.
Vera's lead product candidate is atacicept, a fusion protein that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including Berger's disease and lupus nephritis.
The company's shares were down over 10% in recent trading.
Price: 33.26, Change: -3.77, Percent Change: -10.17
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.